Induction of indoleamine 2, 3-dioxygenase by death receptor activation contributes to apoptosis of melanoma cells via mitochondrial damage-dependent ROS …

Share Embed


Descrição do Produto

Cellular Signalling 23 (2011) 948–949

Contents lists available at ScienceDirect

Cellular Signalling j o u r n a l h o m e p a g e : w w w. e l s ev i e r. c o m / l o c a t e / c e l l s i g

Corrigendum

Corrigendum to “Induction of indoleamine 2, 3-dioxygenase by death receptor activation contributes to apoptosis of melanoma cells via mitochondrial damage-dependent ROS accumulation” [Cell. Signalling 22 (2010) 197–211] Turgut Cetindere a, Sandeep Nambiar a, Simeon Santourlidis b, Frank Essmann c, Mohamed Hassan a,d,e,⁎ a

Clinic of Dermatology, University Hospital of Duesseldorf, Duesseldorf, Germany Institute of Transplantation and Cell Therapeutic, University Hospital of Duesseldorf, Duesseldorf, Germany c Interfaculty Institute of Biochemistry, Faculty of Medicine, Eberhard Karls University of Tuebingen, Germany d Institut National de la Santé et de la Recherché Médicale, Unité 595, Faculty of Medicine, Strasbourg, France e Dental Faculty, University of Louis Pasteur, Strasbourg, France b

The authors regret that there were errors in Figs. 1B, 2C, 3D, and 3E of the above publication. The corrected versions of the figures are reproduced here. The corrections do not influence either the validity of the published data or the conclusions described in the article. We apologise for these mistakes.

Fig. 1B.

DOI of original article: 10.1016/j.cellsig.2009.09.013. ⁎ Corresponding author at: Clinic of Dermatology, University Hospital of Duesseldorf, Duesseldorf, Germany. Tel.: + 49 211 811 6402; fax: + 49 211 811 8840. E-mail address: [email protected] (M. Hassan). 0898-6568/$ – see front matter © 2011 Elsevier Inc. All rights reserved. doi:10.1016/j.cellsig.2011.01.008

T. Cetindere et al. / Cellular Signalling 23 (2011) 948–949

Fig. 2C.

Fig. 3D.

Fig. 3E.

949

Lihat lebih banyak...

Comentários

Copyright © 2017 DADOSPDF Inc.